Evolva Holding SA / Key word(s): Half Year Results Evolva with record half-yearly sales and new mid-term plan 25-Aug-2022 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Reinach, 25 August 2022 – Evolva (SIX:EVE) achieved record half-yearly sales in 2022 with total revenues of CHF 8.1 million. Product-related sales grew 30% to CHF 7.8 million against a high basis from the prior year period, especially driven by Vanillin. Evolva is well on track to reach its sales guidance of CHF 15 million for the full year. The gross contribution margin of product-related sales was 10.9% in the first half and hence already in line with the targeted double digit margin for the full year. The new mid-term plan foresees annual revenue growth of 40-60% with the target to reach a revenue level of CHF 45-50 million in 2025 with EBITDA and cashflow break-even in 2025. Business and corporate highlights:
Targets of new mid-term plan:
Financial highlights:
Outlook:
Christian Wichert, CEO of Evolva, commented: “We at Evolva are on a mission to take the company from a research & development focused boutique to the next level of development based on the strong momentum we achieved in the first half of 2022 and our attractive product portfolio. We have set ourselves clear priorities for 2022 and the mid-term.
Christian Wichert added on the targets of the mid-term plan: “To be conservative, our mid-term plan is largely based on the existing product portfolio where we already have better visibility. We aim to become an industrial biotech leader, providing solutions around natural ingredients addressing the global megatrends of health, wellness and sustainability. Based on our proprietary precision-fermentation platform, we are uniquely positioned to resolve supply bottlenecks of nature. Thanks to our knowhow in process development and our ability of scaling up processes from the lab to industrial production, Evolva is set to benefit from global market trends and ensuing opportunities.”
Key figures1)
1) This table includes references to operational indicators and alternative performance measures (AMP) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and as substitutes to the Group’s consolidated financial results based on IFRS.
Documentation The Half-Year Report 2022 as well as the HY 2022 results presentation are available at https://evolva.com/financial-data/hy-results/
Webcast and Conference Call Evolva will hold a conference call with media and the financial community today, at 10.00 a.m. CET. Dial-in details: CH: +41 (0)44 580 7279 DE: +49 (0)69 22222 5197 UK: +44 (0)330 165 4012 US: +1 646-828-8073 Confirmation Code: 8538292
Webcast-Link for conference call participants: https://www.webcast-eqs.com/evolva25082022/no-audio Webcast-Link to the Livestream: https://www.webcast-eqs.com/evolva25082022 To ask questions during the Q+A session you must dail in to the moderated telephone conference. A replay will be available after the call on the Evolva website.
Important dates 21 September 2022: Investora Zurich 09 March 2023: Full-year 2022 results 18 April 2023: Annual General Meeting
Contact Doris Rudischhauser Head of Investor Relations and Corporate Communications +41 79 410 81 88
About Evolva Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at evolva.com and connect with us on LinkedIn. For Evolva multimedia content, please visit: evolva.com/multimedia-library. Disclaimer This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. End of Inside Information |
Language: | English |
Company: | Evolva Holding SA |
Duggingerstrasse 23 | |
4153 Reinach | |
Switzerland | |
Phone: | +41 61 485 20 00 |
Internet: | www.evolva.com |
ISIN: | CH0021218067 |
Valor: | 2121806 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1427773 |
End of Announcement | EQS News Service |
|
1427773 25-Aug-2022 CET/CEST